NCTN Lymphoma Trials Portfolio (Open as of 9/15/2021) Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information. Relapsed or refractory A051301 Diffuse large Newly diagnosed, including MYC/BCL2 B-cell S1918 double-expressing and transformed lymphoma Inclduing MYC/BCL2 double-expressing A051701 High-grade Newly diagnosed, MYC/BCL2/BCL6 double or S1918 B-cell triple rearragement lymphoma A051701 Follicular Newly diagnosed, Grade IIIB S1918 lymphoma Relapsed or refractory S1608 Lymphoplasmacytic lymphoma Previously untreated S2005 (Waldenstrom macroglobulinemia) Untreated, with cyclin D1 (BCL1) EA4181 Mantle cell expression and/or t(11;14) lymphoma Evaluation of transplant & minimal residual EA4151 disease post initial induction therapy Lymphoma Previously untreated, Peripheral T-cell lymphoma A051902 CD30 negative Precursor T-lymphoblastic Relapsed or refractory S1905 lymphoma Chronic Lymphocytic Leukemia / Newly diagnosed, S1925 Small lymphocytic lymphoma Asymptomatic, High-risk Newly diagnosed, No evidence of Primary CNS lymphoma A051901 NHL outside CNS Classical Newly diagnosed, Untreated, Stage III/IV S1826 Hodgkin lymphoma Relapsed or refractory E4412 Cross-disease trial: EAY131 (MATCH) NCTN Lymphoma Trials (Open as of 9/15/2021) Protocol Number Phase Protocol Title A Randomized Double‐Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma of A051301 III the Activated B‐cell Subtype Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double‐ A051701 II/III Hit and Double Expressing Lymphomas Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo‐MR2) Induction Followed by A051901 I Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma A Randomized Phase II Study of CHO(E)P vs CC‐486‐CHO(E)P vs Duvelisib‐CHO(E)P in Previously Untreated A051902 II CD30 Negative Peripheral T‐Cell Lymphomas A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, E4412 I/II Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell EA4151 III Lymphoma in Minimal Residual Disease‐Negative First Complete Remission A Randomized 3‐Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR‐A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR‐A) in Patients <= 70 Years Old with Untreated Mantle Cell EA4181 II Lymphoma S1608 II Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus S1826 III AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma A Phase I/II Study of AKR1C3‐Activated Prodrug OBI‐3424 (OBI‐3424) In Patients with Relapsed/Refractory S1905 II T‐Cell Acute Lymphoblastic Leukemia (T‐ALL)/T‐Cell Lymphoblastic Lymphoma (T‐LBL) A Phase II/III Randomized Study of R‐MiniCHOP with or Without CC‐486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High‐Grade B‐Cell Lymphomas with MYC AND BCL2 and/or S1918 II/III BCL6 Rearrangements Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High‐Risk Patients with S1925 III Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously S2005 II Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) EAY131 II Molecular Analysis for Therapy Choice (MATCH) This portfolio shows NCTN trials. For information about NCORP trials, please see: https://ncorp.cancer.gov/find‐a‐study/.